Nusinersen
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1108 publications
Real-world pharmacoclinical implementation of risdiplam under a national SMA protocol: A hospital pharmacy registry-based case series.
Journal: Pakistan journal of pharmaceutical sciences
Published: August 22, 2026
Nusinersen for type-III spinal muscular atrophy: a 12-month retrospective study in a Brazilian cohort.
Journal: Arquivos de neuro-psiquiatria
Published: July 17, 2026
Managing nusinersen therapy during pregnancy in spinal muscular atrophy type 3.
Journal: BMJ case reports
Published: July 15, 2026
Anesthesia Care, Complications, and Airway Management for Patients With Spinal Muscular Atrophy: A Retrospective Chart Review From a Quaternary Children's Hospital.
Journal: Anesthesia and analgesia
Published: June 27, 2026
Exploring Treatment Expectations and Clinical Meaningfulness in Spinal Muscular Atrophy Using the Goal Attainment Scale.
Journal: Archives of rehabilitation research and clinical translation
Published: June 22, 2026
Brain Morphological Alterations in Adults with Spinal Muscular Atrophy Types 2 and 3: A CAT12-Derived Region-Based and Surface-Based Morphometry Study.
Journal: Journal of clinical medicine
Published: June 17, 2026
Correction: Clinical outcome and efficacy of nusinersen in Korean adult patients with 5q spinal muscular atrophy: Nationwide multicenter retrospective study.
Journal: Acta neurologica Belgica
Published: May 28, 2026
Ten years of disease-modifying therapy in spinal muscular atrophy: lessons learned and future directions.
Journal: Nature reviews. Neurology
Published: May 26, 2026
Nusinersen: the antisense oligonucleotide at the forefront of spinal muscular atrophy treatment.
Journal: RNA biology
Published: May 18, 2026
Lung Function and Respiratory Muscle Strength in Symptomatic Children and Adults With Spinal Muscular Atrophy Treated With Nusinersen.
Journal: Neurology
Published: May 07, 2026
Last Updated: 09/26/2026